Homburger advises the joint book-running managers in connection with the public offering of up to 4,842,104 common shares in CRISPR Therapeutics AG
On September 19, 2018, CRISPR Therapeutics AG, a biopharmaceutical company based in Zug, Switzerland, focusing on the development of transformative gene-based medicines for serious diseases, a selling shareholder and Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC, as joint book-running managers and representatives of the several underwriters, entered into an underwriting agreement relating to the public offering of 4,210,526 common shares at a price of USD 47.50 per share, before underwriting discounts. Pursuant to the underwriting agreement, CRISPR Therapeutics AG and a selling shareholder have granted the underwriters an option to purchase within 30 days from the date of the underwriting agreement up to an additional 631,578 common shares in CRISPR Therapeutics AG. The gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, are expected to be approximately USD 200 m or approximately USD 230 m, assuming no exercise or full exercise, respectively, of the over-allotment option. The offering is expected to close on or about September 25, 2018 and no later than October 24, 2018 in connection with the over-allotment option, in each case subject to customary closing conditions.
Homburger AG is acting as legal counsel to Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC as the joint book-running managers and representatives of the several underwriters in the offering. The Homburger team is led by partner Frank Gerhard (Corporate / M&A) and comprises associates Céline Martin (Tax), Dominik Aerni and Lorenzo Togni (both Corporate / M&A).